RDGL on OTC

VIVOS INC

VIVOS INC is an American surgical and medical instruments and apparatus company.1 It is headquartered in Richland, Washington.1 Its shares trade on OTC under the symbol RDGL.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with PAVmed Inc., Fractyl (United States) or Profusa, Inc., or pick any stock.

  • TickerRDGL on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersRichland, Washington1
  • Incorporated inDE2
  • Business address719 Jadwin Avenue, Richland, Wa 993522
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

FDA does not exercise premarket authority over veterinary devices, and manufacturers bear responsibility for ensuring ongoing compliance.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-87.4%Gross margin4
-4628.7%Operating margin4
-4483.9%Net margin4
144.3%Revenue growth, 20254
-184.6%Return on equity4
-$2.2MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

IsoPet brought in 53% of the revenue VIVOS INC broke down this way in fiscal 2025.

  1. IsoPet$143.0K453%
  2. Services Treatments$88.9K433%up 196% from 2024
  3. Certification$37.5K414%
  4. Polymer$1.1K40%
  5. Freight$1.1K40%
Products and services by year
Products and services20242025
IsoPet$143.0K
Services Treatments$30.0K$88.9K
Certification$37.5K
Polymer$1.1K
Freight$1.1K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue27¢$128.1K
  • Research and development73¢$352.2K

Out of $68.4K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$68.4K in 2025+620% since 2019
0$20.0K$40.0K$60.0K$80.0K2019: $9.5K$9.5K20192020: $7.0K$7.0K2020−26%2021: $14.9K$14.9K2021+113%2022: $36.5K$36.5K2022+145%2023: $19.5K$19.5K2023−47%2024: $28.0K$28.0K2024+44%2025: $68.4K$68.4K2025+144%
Gross profit567894-$59.8K in 2025
-$60.0K-$40.0K-$20.0K0$20.0K2019: $3.5K$3.5K20192020: $1.4K$1.4K2020−60%2021: $2.9K$2.9K2021+107%2022: $7.7K$7.7K2022+167%2023: -$6.0K-$6.0K20232024: -$3.0K-$3.0K2024−51%2025: -$59.8K-$59.8K2025+1903%
Operating income567894-$3.2M in 2025+138% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$1.3M-$1.3M20192020: -$672.5K-$672.5K2020−49%2021: -$2.5M-$2.5M2021+272%2022: -$2.5M-$2.5M2022+1%2023: -$2.8M-$2.8M2023+11%2024: -$2.6M-$2.6M2024−7%2025: -$3.2M-$3.2M2025+22%
Net income567894-$3.1M in 2025+90% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$1.6M-$1.6M20192020: -$957.0K-$957.0K2020−41%2021: -$2.5M-$2.5M2021+164%2022: -$2.5M-$2.5M2022−2%2023: -$2.9M-$2.9M2023+17%2024: -$2.9M-$2.9M2024+1%2025: -$3.1M-$3.1M2025+5%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues, net$68.4K$28.0K
Cost of Goods Sold$128.1K$31.0K
Gross (loss) profit-$59.8K-$3.0K
Professional fees, including stock-based compensation$2.0M$1.7M
Payroll expenses$417.1K$352.6K
Research and development$352.2K$324.6K
General and administrative expenses$296.6K$241.8K
Total Operating Expenses$3.1M$2.6M
OPERATING LOSS-$3.2M-$2.6M
Interest income$99.0K$74.9K
Loss on issuance of shares and warrant exchange-$381.0K
Total Non-Operating Income$99.0K-$306.1K
NET LOSS BEFORE PROVISION FOR INCOME TAXES-$3.1M-$2.9M
NET LOSS-$3.1M-$2.9M
Net loss per share - basic-$0.01-$0.01
Net loss per share - diluted-$0.01-$0.01
Weighted average common shares outstanding - basic452.7M shares409.7M shares
Weighted average common shares outstanding - diluted452.7M shares409.7M shares

Compare VIVOS INC with another company

What it owns

What VIVOS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$3744 Dec 31, 2025$15.2K12 Dec 31, 2017−97.5%
Property and equipment, net$102.8K4 Dec 31, 2025$1.5K12 Dec 31, 2016+6879.7%
Operating-lease assets (leased space)$110.7K4 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.2M9 Dec 31, 2024$1.6M8 Dec 31, 2023+39.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$57.3K4 Dec 31, 2025$8.5K12 Dec 31, 2017+575.6%

Properties, in its own words

The Company is headquartered in Kennewick, Washington. Our Chief Executive Officer currently works from his home office in virtual communication with key personnel. Cadwell Laboratories, which is controlled by Carl Cadwell, a director of the Company, provides office space to management on an as-needed basis until such time as the Company leases permanent office space. Management believes that the Company’s sites are adequate to support the business and suitable for present purposes, and the properties and equipment have been well maintained.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led VIVOS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. James C. Katzaroff2009–2016
  2. Michael K. Korenko2017–now

President

  1. James C. Katzaroff2010–2013
  2. Michael K. Korenko2017–2026
  3. Brad Allan Weeks2026–now

Chief financial officer

  1. Leonard Bruce Jolliff2010–2018
  2. Michael H. Pollack2018–2023
2010201520202025
Board members and other officers (6)

Former names

  • ADVANCED MEDICAL ISOTOPE CorpNov 12, 2008 to Dec 18, 20172

Timeline

  1. Oct 8, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights24
  2. Oct 5, 20268-K Bylaws or fiscal year changed25
  3. Sep 24, 20258-K Entered a material agreement; Executive or director change26
  4. Sep 22, 20258-K Entered a material agreement; Executive or director change27
  5. Sep 18, 20258-K Other events28
  6. Feb 10, 20258-K Unregistered sale of shares; Other events29
  7. Feb 10, 20258-K Other events30
  8. Jul 1, 20248-K Other events31
  9. Mar 25, 20248-K Entered a material agreement; Executive or director change32
  10. Dec 27, 20238-K Unregistered sale of shares; Other events33
  11. Oct 11, 20238-K Other events34
  12. May 2, 20238-K Unregistered sale of shares; Other events35
  13. Jan 9, 2017New chief executive Michael K. Korenko becomes CEO13
  14. Jan 28, 2009New chief executive James C. Katzaroff becomes CEO14

Filings

93 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 14 major events, 33 insider forms, 26 other. The latest 20:

  1. Oct 8, 20268-K EDGAR
  2. Oct 8, 20264 EDGAR
  3. Oct 5, 20268-K EDGAR
  4. Oct 1, 20264 EDGAR
  5. Sep 16, 20264 EDGAR
  6. Aug 12, 202610-Q EDGAR
  7. Aug 10, 20264 EDGAR
  8. Aug 10, 20264 EDGAR
  9. Jul 22, 20264 EDGAR
  10. Jul 15, 20264/A EDGAR
  11. Jul 15, 20265 EDGAR
  12. Jul 15, 20264 EDGAR
  13. Jul 10, 20264 EDGAR
  14. May 14, 202610-Q EDGAR
  15. May 11, 20264 EDGAR
  16. Apr 28, 20263 EDGAR
  17. Mar 31, 202610-K EDGAR
  18. Mar 5, 2026QUALIF EDGAR
  19. Mar 4, 2026CORRESP EDGAR
  20. Mar 4, 20261-A/A EDGAR

The 93 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

30 open-market trades by officers, directors and large owners since October 2021: 29 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026Weeks Brad AllanPresidentBuy25,550$0.05$1.3KForm 4
Aug 10, 2026Weeks Brad AllanPresidentBuy50,000$0.05$2.5KForm 4
Aug 10, 2026Korenko Michael KCEO AND PRESIDENTBuy150,000$0.05$7.5KForm 4
Jul 22, 2026Weeks Brad AllanPresidentBuy32,000$0.05$1.6KForm 4
Jul 21, 2026Weeks Brad AllanPresidentBuy60,000$0.05$3.0KForm 4
Jul 15, 2026Korenko Michael KCEO AND PRESIDENTBuy200,000$0.06$12.0KForm 4
Jul 10, 2026Weeks Brad AllanPresidentBuy12,000$0.08$960Form 4
Jul 10, 2026Weeks Brad AllanPresidentBuy12,000$0.08$960Form 4
Jul 9, 2026Weeks Brad AllanPresidentBuy48,000$0.08$3.8KForm 4
Jul 9, 2026Weeks Brad AllanPresidentBuy48,000$0.08$3.8KForm 4
May 11, 2026Korenko Michael KCEO AND PRESIDENTBuy150,000$0.06$9.0KForm 4
Dec 31, 2025Korenko Michael KCEO AND PRESIDENTBuy200,000$0.06$12.0KForm 4
Dec 2, 2025Korenko Michael KCEO AND PRESIDENTBuy100,000$0.07$7.0KForm 4
Nov 20, 2025Korenko Michael KCEO AND PRESIDENTBuy100,000$0.06$6.0KForm 4
Aug 14, 2025Korenko Michael KCEO AND PRESIDENTBuy100,000$0.08$8.0KForm 4
Oct 28, 2024Korenko Michael KCEO AND PRESIDENTBuy50,000$0.14$7.0KForm 4
Sep 30, 2024Korenko Michael KCEO AND PRESIDENTBuy50,000$0.16$8.0KForm 4
Aug 13, 2024Korenko Michael KCEO AND PRESIDENTBuy50,000$0.11$5.5KForm 4
Aug 7, 2024Korenko Michael KCEO AND PRESIDENTBuy50,000$0.12$6.0KForm 4
Aug 1, 2024Korenko Michael KCEO AND PRESIDENTBuy50,000$0.09$4.5KForm 4

All 30 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

SEC filer profile

How VIVOS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVIVOS INC1
  • CIK0001449349
  • Employer ID (EIN)80-01389373
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address719 Jadwin Avenue, Richland, WA 993521
  • Phone509-736-40001
  • Shares outstanding494,214,360 as of Aug 12, 202611
  • Public float$47.7M as of Jun 30, 20253
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceNov 12, 20081
  • Filings496 in all: 4 (150), 8-K (71), 10-Q (53), 5 (34), UPLOAD (27), CORRESP (20), 10-K (18), 4/A (13)1
    All 37 form types

    NT 10-Q (10), 1-A POS (9), 10-Q/A (8), 3 (8), QUALIF (8), 10-12G/A (6), 10-K/A (6), 1-A/A (5), 1-A (4), 8-K/A (4), D (4), S-1/A (4), 253G2 (3), DEF 14A (3), DEF 14C (3), NT 10-K (3), PRE 14A (3), PRE 14C (3), SC 13G (3), S-1 (2), S-8 (2), SC 13G/A (2), 10-12G (1), 5/A (1), DEFR14C (1), EFFECT (1), RW (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Jul 10, 2017
    Latest 8-K (8-K) Oct 8, 2026

Risk factors and legal proceedings

The risks VIVOS INC names in Item 1A of its 10-K filed Mar 31, 2026: 35 risks under these headings, as written.3

  • RISKS ASSOCIATED WITH THE COMPANY’S BUSINESS
  • Our independent registered public accounting firms’ reports on its financial statements questions the Company’s ability to continue as a going concern.
  • A combination of our current financial condition and the United States Food and Drug Administration’s (“FDA”) determinations to date regarding Radiogel™ raise material concerns about ability to continue as a going concern.
  • The Company has generated operating losses since inception, which are expected to continue, and has increasing cash requirements, which it may be unable to satisfy.
  • The Company has a limited operating history, which may make it difficult to evaluate its business and prospects.
  • The Company’s products are regulated and require appropriate clearances and approvals to be marketed in the U.S. and globally.
  • If the Company is successful in increasing the size of its organization, the Company may experience difficulties in managing growth.
  • The Company’s business is dependent upon the continued services of the Company’s Chief Executive Officer, Michael Korenko. Should the Company lose the services of Dr. Korenko, the Company’s operations will be negatively impacted.
  • The Company is heavily dependent on consultants for many of the services necessary to continue operations. The loss of any of these consultants could have a material adverse effect on the Company’s business, results of operations and financial condition.
  • If the Company is unable to hire and retain additional qualified personnel, the business and financial condition may suffer.
  • The Company’s revenues have historically been derived from sales made to a small number of customers. The Company has discontinued prior operations related to its core business. To succeed, we will need to recommence our operations and achieve sales to a materially larger number of customers.
  • Many of the Company’s competitors have greater resources and experience than the Company has.
The other 24 risks
  • The Company’s future revenues depend upon acceptance of its current and future products in the markets in which they compete.
  • The Company currently relies on a single supplier for Y-90 particles, and that supplier is the only supplier in the United States. An inability to procure Y-90 particles will materially harm the Company’s business.
  • The Company relies on a sole manufacturing contact with IsoTherapeutics.
  • The Company will rely heavily on a limited number of suppliers for the foreseeable future.
  • The Company may incur material losses and costs because of product liability claims that may be brought against it.
  • The Company is subject to the risk that certain third parties may mishandle the Company’s products.
  • The Company is subject to uncertainties regarding reimbursement for use of its products.
  • The Company’s future growth is largely dependent upon its ability to develop new technologies that achieve market acceptance with appropriate margins.
  • The Company may rely on third parties to represent it locally in the marketing and sales of its products in international markets and its revenue may depend on the efforts and results of those third parties.
  • The Company may pursue strategic acquisitions that may have an adverse impact on its business.
  • The Company will need to hire additional qualified accounting personnel in order to remediate a material weakness in its internal control over financial accounting, and the Company will need to expend any additional resources and efforts that may be necessary to establish and to maintain the effectiveness of its internal control over financial reporting and its disclosure controls and procedures.
  • The Company’s patented or other technologies may infringe on other patents, which may expose us to costly litigation.
  • Protecting the Company’s intellectual property is critical to its innovation efforts.
  • The Company may not be able to protect its trade secrets and other unpatented proprietary technology, which could give competitors an advantage.
  • The Company is subject to extensive government regulation in jurisdictions around the world in which it does business. Regulations address, among other things, environmental compliance, import/export restrictions, healthcare services, taxes and financial reporting, and those regulations can significantly increase the cost of doing business, which in turn can negatively impact operations, financial results, and cash flow.
  • RISKS RELATED TO THE COMPANY’S COMMON STOCK
  • The Company’s common stock is currently quoted on the OTCQB Marketplace. Failure to develop or maintain a more active trading market may negatively affect the value of the Company’s common stock, may deter some potential investors from purchasing the Company’s common stock or other equity securities, and may make it difficult or impossible for stockholders to sell their shares of common stock.
  • The Company’s outstanding securities, the stock or other securities that it may become obligated to issue under existing agreements, and certain provisions of those securities, may cause immediate and substantial dilution to existing stockholders and may make it more difficult to raise additional equity capital.
  • Future sales of the Company’s securities, including sales following exercise or conversion of derivative securities, or the perception that such sales may occur, may depress the price of common stock, and could encourage short sales.
  • The Company’s stock price is likely to be volatile.
  • The Company’s common stock is subject to the “Penny Stock” rules of the SEC and the trading market in its securities is limited, which makes transactions in its common stock cumbersome and may reduce the value of an investment in the Company’s stock.
  • As a result of the Company issuing preferred stock, the rights of holders of the Company’s common stock and the value of the Company’s common stock may be adversely affected.
  • The Company does not expect to pay any dividends on common stock for the foreseeable future.
  • GENERAL RISK FACTORS
  • Volatility in raw material and energy costs, interruption in ordinary sources of supply, and an inability to recover from unanticipated increases in energy and raw material costs could result in lost sales or could increase significantly the cost of doing business.
  • General economic conditions in markets in which the Company does business can impact the demand for the Company’s goods and services. Decreased demand for the Company’s products and services could have a negative impact on its financial performance and cash flow.

Legal proceedings

The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. There are no material pending or threatened legal proceedings at this time.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35